MARC Record from marc_columbia

LEADER: 06691cam a22009974a 4500
001 4889950
005 20221109193826.0
008 040920t20042004nyu b 001 0 eng
010 $a 2004041212
016 7 $a101230403$2DNLM
019 $a174056049$a708341684$a1022611957
020 $a0375508465$q(cloth ;$qalk. paper)
020 $a9780375508462$q(cloth ;$qalk. paper)
020 $a9780375760945
020 $a0375760946
035 $a(OCoLC)ocm54035188
035 $a(OCoLC)54035188$z(OCoLC)174056049$z(OCoLC)708341684$z(OCoLC)1022611957
035 $a(NNC)4889950
035 $a4889950
040 $aDLC$beng$cDLC$dKUT$dDNJ$dNLM$dNOR$dOCL$dBAKER$dMUQ$dNLGGC$dNSB$dYDXCP$dOCLCQ$dBTCTA$dDEBSZ$dIG#$dOCLCO$dOCLCF$dBEDGE$dOCLCQ$dOCLCO$dEUX$dWB9GB$dOCLCQ$dDEBBG$dOCLCQ$dCSJ$dOCLCO$dFM0$dOCLCA$dXBE$dOCLCQ$dCCH
042 $apcc
043 $an-us---
050 00 $aHD9666.5$b.A74 2004
060 00 $a2004 K-782
060 10 $aQV 736$bA583t 2004
082 00 $a338.4/36151/0973$222
084 $a44.42$2bcl
100 1 $aAngell, Marcia.$0http://id.loc.gov/authorities/names/n81009499
245 14 $aThe truth about the drug companies :$bhow they deceive us and what to do about it /$cMarcia Angell.
250 $a1st ed.
260 $aNew York :$bRandom House,$c[2004], ©2004.
300 $axx, 305 pages ;$c25 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
504 $aIncludes bibliographical references and index.
505 0 $aIntroduction : Drugs are different -- 1. The $200 billion colossus -- 2. The creation of a new drug -- 3. How much does the pharmaceutical industry really spend on R & D? -- 4. Just how innovative is this industry? -- 5. "Me-too" drugs : the main business of the pharmaceutical industry -- 6. How good are new drugs? -- 7. The hard sell : lures, bribes, and kickbacks -- 8. Marketing masquerading as education -- 9. Marketing masquerading as research -- 10. Patent games : stretching out monopolies -- 11. Buying influence : how the industry makes sure it gets its way -- 12. Is the party over? -- 13. How to save the pharmaceutical industry--and get our money's worth -- Afterword.
520 $aAngell watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless influence over medical research, education, and how doctors do their jobs. She sympathized as the American public, particularly the elderly, struggled and increasingly failed to meet spiraling prescription drug prices.
520 1 $a"During her two decades at The New England Journal of Medicine, Dr. Marcia Angell had a front-row seat on the growing corruption of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless influence over medical research, education, and how doctors do their jobs. She sympathized as the American public, particularly the elderly, struggled with and increasingly failed to keep up with spiraling prescription drug prices. Now, in this new book, Angell exposes the truth of what the pharmaceutical industry has become - and argues for essential, long-overdue change."--BOOK JACKET.
650 0 $aPharmaceutical industry$zUnited States$xCosts.
650 0 $aDrugs$xPrices$zUnited States.$0http://id.loc.gov/authorities/subjects/sh2008102459
650 0 $aDrugs$xResearch$zUnited States$xFinance.
650 0 $aPrescription pricing$zUnited States.$0http://id.loc.gov/authorities/subjects/sh2008109174
650 0 $aAdvertising$xDrugs$zUnited States.
650 0 $aPharmaceutical policy$zUnited States.$0http://id.loc.gov/authorities/subjects/sh2008109173
650 12 $aDrug Industry$xeconomics.$0(DNLM)D004345Q000191$0https://id.nlm.nih.gov/mesh/D004345Q000191
650 22 $aAdvertising.$0(DNLM)D000329$0https://id.nlm.nih.gov/mesh/D000329
650 22 $aPharmaceutical Preparations$xeconomics.$0(DNLM)D004364Q000191$0https://id.nlm.nih.gov/mesh/D004364Q000191
650 12 $aDrug Industry$xeconomics.$0https://id.nlm.nih.gov/mesh/D004345Q000191
650 22 $aPharmaceutical Preparations$xeconomics.$0https://id.nlm.nih.gov/mesh/D004364Q000191
650 22 $aAdvertising.$0https://id.nlm.nih.gov/mesh/D000329
651 2 $aUnited States.$0(DNLM)D014481$0https://id.nlm.nih.gov/mesh/D014481
650 6 $aIndustrie pharmaceutique$zÉtats-Unis$xCoût.
650 6 $aMédicaments$xPrix$zÉtats-Unis.
650 6 $aMédicaments$xRecherche$zÉtats-Unis$xFinances.
650 6 $aMédicaments$xPublicité$zÉtats-Unis.
650 6 $aMédicaments$xPolitique gouvernementale$zÉtats-Unis.
650 7 $aIndustrie pharmaceutique.$2eclas
650 7 $aFixation des prix.$2eclas
650 7 $aMarketing.$2eclas
650 7 $aBrevets.$2eclas
650 7 $aPublicité.$2eclas
651 7 $aEtats-Unis d'Amérique.$2eclas
650 7 $aAdvertising$xDrugs.$2fast$0(OCoLC)fst00797609
650 7 $aDrugs$xPrices.$2fast$0(OCoLC)fst00898879
650 7 $aDrugs$xResearch$xFinance.$2fast$0(OCoLC)fst00898900
650 7 $aPharmaceutical industry$xCosts.$2fast$0(OCoLC)fst01060134
650 7 $aPharmaceutical policy.$2fast$0(OCoLC)fst01060194
650 7 $aPrescription pricing.$2fast$0(OCoLC)fst01075656
651 7 $aUnited States.$2fast$0(OCoLC)fst01204155
650 17 $aFarmaceutische industrie.$2gtt
650 17 $aWinst.$2gtt
650 17 $aEthiek.$2gtt
650 4 $aIndustrie pharmaceutique$xÉtats-Unis$xCoût.
650 4 $aMédicaments$xPolitique gouvernementale$xÉtats-Unis.
650 4 $aMédicaments$xPrix$xÉtats-Unis.
650 4 $aMédicaments$xPublicité$xÉtats-Unis.
650 4 $aMédicaments$xRecherche$xÉtats-Unis$xFinances.
776 08 $iOnline version:$aAngell, Marcia.$tTruth about the drug companies.$b1st ed.$dNew York : Random House, ©2004$w(OCoLC)607579749
856 41 $3Sample text$uhttp://catdir.loc.gov/catdir/samples/random051/2004041212.html
856 41 $3Table of contents$qtext/html$uhttp://swbplus.bsz-bw.de/bsz114379165inh.htm
856 42 $3Contributor biographical information$uhttp://catdir.loc.gov/catdir/bios/random051/2004041212.html
856 42 $3Publisher description$uhttp://catdir.loc.gov/catdir/description/random051/2004041212.html
852 00 $boff,bus$hHD9666.5$i.A74 2004
852 00 $bsci$hHD9666.5$i.A74 2004
852 00 $bjou$hHD9666.5$i.A74 2004